Sign in Subscribe
Diseases

Cost-Effectiveness of COPDPredict System in Predicting and Preventing Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Strategic Insights

— 2 min read

A new study published in the International Journal of COPD has investigated the cost-effectiveness of a personalized early warning decision support system, COPDPredict, in predicting and preventing acute exacerbations of chronic obstructive pulmonary disease (COPD). The research, conducted by the Institute for Applied Health Research, found that COPDPredict was potentially cost-effective for COPD patients with a 65% likelihood of cost-effectiveness at a willingness to pay of £20,000 per quality-adjusted life-year (QALY).

Key Takeaways:

  • The study aimed to evaluate the cost-effectiveness of COPDPredict, a digital tool that supports patients in identifying exacerbations earlier to reduce hospital admissions.
  • The research involved a trial-based cost-utility and cost-effectiveness analysis from the UK National Health Service perspective, comparing the cost-effectiveness of COPDPredict with usual care for a COPD GOLD stage B and D cohort.
  • The analysis showed that at a willingness to pay of £20,000 per QALY, COPDPredict was 65% likely cost-effective in COPD B and D patients over 6 months.
  • The incremental cost-effectiveness ratio (ICER) was £11,669/QALY, with a similar ICER of £11,862/QALY obtained when performing model-based analysis over 5 years.
  • The results were robust to complete case analyses over 6- and 12-months, but sensitive to long-term effectiveness, cost parameters, and alternative model structure.

Statistics:

  • £20,000: the willingness to pay per quality-adjusted life-year (QALY) at which COPDPredict was considered cost-effective.
  • 65%: the likelihood of cost-effectiveness of COPDPredict at the willingness-to-pay threshold.
  • £11,669/QALY: the incremental cost-effectiveness ratio (ICER) obtained from the trial-based analysis over 6 months.
  • £11,862/QALY: the ICER obtained from the model-based analysis over 5 years.
  • 0.02: the increase in quality-adjusted life-years (QALYs) obtained from the trial-based analysis over 6 months.
  • 0.012: the increase in QALYs obtained from the complete case analysis over 12 months.
  • 5 years: the time horizon for the model-based analysis.
  • £238.16: the incremental cost obtained from the trial-based analysis over 6 months.
  • 106.42: the incremental cost obtained from the complete case analysis over 12 months.

Sources:

  • The Cost-Effectiveness of a Personalised Early Warning Decision Support System (The COPDPredict System) to Predict and Prevent Acute Exacerbations of Chronic Obstructive Pulmonary Disease. International Journal of COPD, 2025, Volume 20(Issue 1):1693-1710. (International Journal of COPD - http://www.dovepress.com/international-journal-of-copd-journal)
  • Institute for Applied Health Research, Health and Medicine, Lung Diseases and Conditions, Chronic Obstructive Pulmonary Disease

Read more